Work

Ctni-35. Survival Benefit of Adding Osimertinib to Standard Salvage Treatment Regimens for Recurrent Glioblastoma (gbm) With Epidermal Growth Factor Receptor (egfr) Alterations

Year: 2025

Type: article

Study design: Observational Study

Source: Neuro-Oncology

DOI: 10.1093/neuonc/noaf201.0531

Authors: Zhihua Chen, Mousumi Sinha, Josh Nahm, Sigmund Hsu, Yoshua Esquenazi, Nitin Tandon, Mark Amsbaugh, Angel Blanco, Cornelius Ware, Austin Lu, Jay-Jiguang Zhu

Institutions: The University of Texas Health Science Center at Houston, Texas A&M University

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4416140909

FWCI:

Cites:

Cited by:

Related to: